journal
https://read.qxmd.com/read/23480353/exposure-to-ethinyl-estradiol-prenatally-and-or-after-sexual-maturity-induces-endometriotic-and-precancerous-lesions-in-uteri-and-ovaries-of-mice
#1
JOURNAL ARTICLE
Eiji Koike, Yoshiko Yasuda, Mitsuru Shiota, Masao Shimaoka, Mitsuhiro Tsuritani, Hiroyoshi Konishi, Harufumi Yamasaki, Katsumi Okumoto, Hiroshi Hoshiai
Unrecognizable exposure to estrogenic substance may cause estrogen-dependent diseases, endometriosis and cancer. Pregnant mice (ICR/Jcl, CLEA) were exposed to 0.01 mg ethinyl estradiol (EE2 )/kg per day or vehicle (olive oil) through oral intubation from day 11 to 17 of gestation. They delivered their offspring and raised them. When the experimental female F1 mice were at 8 weeks of age, they were not exposed to EE2 or to the same dose of EE2 or to vehicle twice a week until 20 weeks of age. The control female F1 mice were exposed to the same dose of EE2 or vehicle alone, similarly...
March 2013: Congenital Anomalies
https://read.qxmd.com/read/23480351/down-syndrome-and-personalized-medicine-changing-paradigms-from-genotype-to-phenotype-to-treatment
#2
JOURNAL ARTICLE
Linda L McCabe, Edward R B McCabe
Personalized Medicine represents a paradigm shift in the conceptual framework of research and clinical care. This shift argues that Down syndrome is a treatable condition, and therefore we must invest in research to improve outcomes. Individuals with Down syndrome have varying levels of increased risk for a number of co-morbidities, including infantile spasms and early onset Alzheimer's disease. We will review research in these associated conditions to show how investigators are attempting to identify biomarkers, including genomic, epigenomic, proteomic and metabolomic "signatures" that will predict who may be at risk to develop a specific co-morbidity prior to onset and will provide novel targets for therapeutic development...
March 2013: Congenital Anomalies
https://read.qxmd.com/read/23185968/in-vitro-evaluation-of-gene-expression-changes-for-gonadotropin-releasing-hormone-1-brain-derived-neurotrophic-factor-and-neurotrophic-tyrosine-kinase-receptor-type-2-in-response-to-bisphenol-a-treatment
#3
JOURNAL ARTICLE
Katsuhiko Warita, Tomoko Mitsuhashi, Ken-ichi Ohta, Shingo Suzuki, Nobuhiko Hoshi, Takanori Miki, Yoshiki Takeuchi
We evaluated the effects of bisphenol A (BPA) on embryonic mouse hypothalamic cells. Real-time reverse transcription polymerase chain reaction (RT-PCR) indicated that gonadotropin-releasing hormone 1 (Gnrh1) expression in 0.02-20 μM BPA-treated cells did not differ from that in control cells but decreased significantly in 200 μMBPAtreated cells. The mRNA level for brain-derived neurotrophic factor (Bdnf), which participates in GNRH1 secretory system development, decreased significantly in 200 μM BPA-treated cells, but that for neurotrophic tyrosine kinase, receptor, type 2 (Ntrk2), did not change...
March 2013: Congenital Anomalies
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.